Abstract:Background and Objective The study addresses the need for strong vaccine-induced antibodies against SARS-CoV-2 in immunocompromised hematological malignancy (HM) patients to reduce COVID-19 severity. Despite vaccination efforts, over a third of HM patients remain unresponsive, increasing their risk of severe breakthrough infections. The study aims to leverage machine learning's adaptability to COVID-19 dynamics, efficiently selecting patient-specific features to enhance predictions and improve healthcare strategies. Emphasizing the complex COVID-hematology connection, the focus is on interpretable machine learning to provide valuable insights to clinicians and biologists. Methods The study evaluated a dataset with more than 1600 patients with hematological diseases. The output was the achievement or non-achievement of a serological response after full COVID-19 vaccination. Various machine learning methods were applied, with the best model selected based on metrics like Area Under the Curve (AUC) score, Sensitivity, Specificity, and Matthew Correlation Coefficient (MCC). Individual SHAP values were obtained for the best model, and principal component analysis (PCA) was applied to these values. The patient profiles were then analyzed within identified clusters. Results Support vector machine (SVM) emerged as the best-performing model. PCA applied to SVM-derived SHAP values resulted in four perfectly separated clusters. These clusters, ordered by the probability of generating antibodies. The clusters were characterized by their respective probabilities. Cluster 1, with the second-highest probability (69.91%), included patients with aggressive diseases and factors contributing to increased immunodeficiency. Cluster 2 had the lowest likelihood (33.3%), but the small sample size limited conclusive findings. Cluster 3, representing the majority of the population, exhibited a high rate of antibody generation (84.39%) and a better prognosis compared to Cluster 1. Cluster 4, with a probability of 66.33%, included patients with B-cell non-Hodgkin's lymphoma on corticosteroid therapy. Conclusions The methodology successfully identified four separate clusters of HM patients based on their likelihood of generating antibodies after COVID-19 vaccination. The study suggests the methodology's potential applicability to other diseases, highlighting the importance of interpretable ML in healthcare research and decision-making.

Predicting humoral responses to primary and booster SARS-CoV-2 mRNA vaccination in people living with HIV: a machine learning approach

A Machine Learning approach to identify groups of patients with hematological malignant disorders

Immunogenicity and Determinants of Antibody Response to the BNT162b2 mRNA Vaccine: A Longitudinal Study in a Cohort of People Living with HIV

Evaluation of the Effect of mRNA and Inactivated SARS-CoV-2 Vaccines on the Levels of Cytokines IL-2, IFN-γ, and Anti-RBD Spike SARS-CoV-2 Antibodies in People Living with HIV (PLHIV)

Humoral response after mRNA COVID-19 primary vaccination and single booster dose in people living with HIV compared to controls: A French nationwide multicenter cohort study-ANRS0001s COV-POPART

IL-2-mediated CD4 T-cell activation correlates highly with effective serological and T-cell responses to SARS-CoV-2 vaccination in people living with HIV (PLWH)

Machine learning models based on fluid immunoproteins that predict non-AIDS adverse events in people with HIV

Humoral and cell-mediated immune responses in HIV-vertically infected young patients after three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine

Efficacy of COVID-19 Vaccination in People Living with HIV: A Public Health Fundamental Tool for the Protection of Patients and the Correct Management of Infection

Humoral immune response to inactivated COVID-19 vaccination at the 3rd month among people living with HIV

Using machine learning to predict antibody response to SARS-CoV-2 vaccination in solid organ transplant recipients: the multicentre ORCHESTRA cohort

Extending the Dosing Interval of COVID-19 Vaccination Leads to Higher Rates of Seroconversion in People Living with HIV.

Antibody response against SARS-CoV-2 spike protein in people with HIV after COVID-19 vaccination

Prediction of Interpersonal Personality for People Living with HIV Using Machine Learning

Interleukin-2-mediated CD4 T-cell activation correlates highly with effective serological and T-cell responses to SARS-CoV-2 vaccination in people living with HIV

A prospective cohort-based artificial intelligence evaluation system for the protective efficacy and immune response of SARS-CoV-2 inactivated vaccines

Evaluation of immune status and selected sirtuins in people living with HIV after fully vaccinating for COVID-19

T-Cell Responses to COVID-19 Vaccines and Breakthrough Infection in People Living with HIV Receiving Antiretroviral Therapy

Identifying psychological predictors of SARS-CoV-2 vaccination: A machine learning study

Factors Associated with Neutralizing Antibody Responses following 2-Dose and 3rd Booster Monovalent COVID-19 Vaccination in Japanese People Living with HIV